Scan beyond Intuitive Surgical and explore other robotics and automation players connected to similar hospital and data themes through our hand picked 86 robotics and automation stocks.
To own Intuitive Surgical, you need to be comfortable with a premium priced, procedure driven robotics platform that leans heavily on recurring instruments, accessories and services. pbco, a Simply Wall St Community investor who wrote the Narrative, points out the razor blade style model that depends on keeping systems in use. Aaron Martin joining the board does not change that in the near term.
The short term focus still sits on procedure volumes, hospital capital budgets and how pricing compares with a 52x P/E and recent share price weakness. The biggest operational risk remains any slowdown in system placements or instrument usage. Board level digital expertise appears incremental rather than a material near term catalyst on its own.
There are no fresh operating announcements tied directly to this board change, so the most relevant context is existing execution data. Earnings have grown 17.5% per year over the past 5 years according to pbco, with current net margins at 25.5% and revenue of about US$11.6b. That track record sets a high bar.
Analysts expect earnings growth of about 15.25% per year and revenue growth of roughly 11% per year, which is slower than the broader US market forecasts. In that context, the stock trades on a 52x P/E, above both industry and peer averages. For you as a shareholder, the key question is whether Intuitive Surgical converts digital tools and data into stable procedure volume and margin resilience.
Using those growth and profitability assumptions, pbco’s narrative arrives at a fair value of US$630.48 for Intuitive Surgical. This is based on revenue rising 11.5% a year and a future profit margin of 28.4%, reflecting a mature razor blade style recurring model.
Uncover why Intuitive Surgical's fair value indicates a 42% potential upside to its current price that could close faster than you expect.
Some of the most optimistic analysts frame Intuitive Surgical very differently from pbco, focusing on digital tools as a major upside catalyst rather than just a support act. Before this board news, the bullish group was modeling revenue of about US$17.4b and earnings of roughly US$5.1b by 2029, far above the low end. You should expect those views to evolve as investors reassess what Aaron Martin’s digital health background might mean and then compare several narratives before deciding where you sit.
Explore 8 other Intuitive Surgical fair value estimates, including one that suggests there could be as much as 42% upside from the current price!
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
If this Intuitive Surgical story has sharpened your thinking about quality, risk and income, you can use that same lens to survey a wider opportunity set through the Simply Wall St Screener.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com